Last updated: February 19, 2026
Crinone is a formulation of progesterone used primarily for supporting pregnancy in assisted reproductive treatments and hormone replacement therapy. It is available in various markets, with key suppliers dominating the global supply chain.
Major Manufacturers of Crinone
| Company Name |
Headquarters |
Product Formulation |
Market Share (Estimated) |
Regulatory Status |
Notes |
| Actavis (Teva Pharmaceuticals) |
Israel |
8% Gel, 8% Vaginal Gel (Crinone 8%) |
35-40% |
Approved in US, EU, others |
Major producer; acquired by Teva in 2016 |
| Ferring Pharmaceuticals |
Switzerland |
8% Vaginal Gel (Crinone 8%) |
25-30% |
Approved in multiple regions |
Focuses on reproductive health applications |
| AbbVie (Abbott) |
United States |
4% Crinone Vaginal Gel |
15-20% |
USFDA approved |
Markets in North America; distribution licenses elsewhere |
| Jubilant Biosys |
India |
Various progesterone formulations |
Less than 10% |
Regulatory approval in India |
Supplies regional markets; manufacturing in India |
| Sandoz (Novartis) |
Switzerland |
Generic formulations |
Varies by region |
Approved in multiple countries |
Focus on generics for competitive pricing |
Global Supply Chain Dynamics
- The fragmented market sees key players like Teva (Actavis), Ferring, and AbbVie competing for market share.
- Manufacturing centers are largely located in the USA, Europe, and India.
- Regulatory approvals influence supply availability across regions, with US and EU markets being the most mature.
- Licensing agreements for distribution rights shape regional availability, especially for generics.
Market Penetration and Regional Focus
- North America: Dominated by Teva and AbbVie, both with well-established regulatory clearances.
- Europe: Ferring holds a significant share, with approved formulations across multiple countries.
- Asia-Pacific: Regional players like Jubilant Biosys serve primarily Indian and Southeast Asian markets.
- Latin America and Africa: Limited availability; reliance on imports and regional manufacturers.
Key Regulatory and Supply Considerations
- Regulatory pathways: Drug approvals and patent protections influence market entry.
- Patent expirations: Lead to increased generic manufacturing and pricing competition.
- Manufacturing capacity: Limited by complex formulation processes for progesterone gels.
- Supply disruptions: Caused by manufacturing issues, regulatory delays, or geopolitical factors.
Summary
Crinone's global supply is controlled by a handful of suppliers, with Teva and Ferring representing the primary manufacturers. The market landscape favors generic competition in mature regions but remains constrained by regulatory and manufacturing capacities across emerging markets. Strategic sourcing and licensing arrangements significantly impact regional availability.
Key Takeaways
- Teva and Ferring are the leading suppliers, controlling roughly 60-70% of the global Crinone market.
- Regulatory approvals in the US and EU facilitate widespread access, while regional licensing influences availability elsewhere.
- Manufacturing capacity constraints and patent expirations affect supply dynamics and pricing.
- Regional players, such as Jubilant Biosys, primarily serve local markets with generic formulations.
- Supply stability depends on regulatory clarity, manufacturing capacity, and geopolitical factors.
FAQs
1. Who are the top suppliers of Crinone globally?
Teva Pharmaceuticals (through Actavis) and Ferring Pharmaceuticals represent the leading suppliers, together controlling an estimated 60-70% of the market.
2. In which regions is Crinone most widely available?
North America and Europe have the highest availability due to regulatory approvals. Asia-Pacific markets see regional manufacturers, while Africa and Latin America depend on imports.
3. Are there generic alternatives to Crinone?
Yes, generic formulations produced by companies like Jubilant Biosys and Sandoz are available, especially after patent expirations.
4. What factors influence Crinone supply stability?
Regulatory approval processes, manufacturing capacities, patent statuses, and geopolitical issues impact supply stability.
5. How do regional licensing agreements affect Crinone availability?
Licensing agreements determine which companies can produce or distribute Crinone in specific markets, affecting regional availability and pricing.
References
[1] European Medicines Agency. (2022). Crinone (progesterone) summary.
[2] US Food and Drug Administration. (2021). Approval documents for Crinone.
[3] IMS Health. (2022). Global reproductive health market report.
[4] Ferring Pharmaceuticals. (2023). Corporate portfolio overview.
[5] Teva Pharmaceuticals. (2022). Product pipeline and market strategy.
